Radicava (edaravone)

Help support timely, affordable and equitable access to proven ALS therapies

Radicava (edaravone) is one of only two drugs approved in Canada for ALS, and the first in almost 20 years. Yet, more than one year after its approval by Health Canada, and positive public funding recommendations from both the Canadian Agency for Drugs and Technologies in Health (CADTH) and l’Institut national d’excellence en santé et en services sociaux (INESSS) in Québec, Radicava is still not accessible through public reimbursement.

You can advocate your provincial government to voice the need for Radicava to be made accessible through public reimbursement.

What you can do:

Now that the manufacturer of Radicava has concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), there is no reason for access to Radicava to be further delayed. But with no defined timeframe or transparency in the public reimbursement process, people living with ALS have no sense of how long they will have to wait to access to this drug through public reimbursement. Community advocacy efforts at the provincial level are vital in communicating the urgent unmet need for access to treatment within the ALS community.

Ask the Minister responsible for health in your province to take action!

Meet with your local representative and tell them affordable access to Radicava is needed now!

Download the toolkit for your province to get the tools you need to write your local elected official to request a meeting.

Provincial Reimbursement

The following provinces have made decisions regarding the public reimbursement of Radicava:

  • Quebec: Yes, under the Régie de l’assurance maladie du Québec (RAMQ) formulary (special authorization)
  • Ontario: Yes, with criteria under the Ontario Drug Benefit Formulary (Exceptional Access Program)

Helpful Resources:

Webinars

ALS Canada blog posts:

 

Together we can and will make a difference!